Wednesday, January 11, 2017 11:02:21 AM
Prurisol has similar potential, reflecting the rising value of oral therapies in treating psoriasis. The drug already has performed comparably to Otezla when it was at a similar stage of development. In the current clinical trial, a Phase 2b assessing moderate-to-severe psoriasis, Prurisol might show even greater efficacy after an evaluation of higher dosing regimens, 300mg and 400mg respectively.
“Among systemic-naïve patients with moderate-to-severe psoriasis, there were no statistically significant differences between apremilast and methotrexate. In addition, the [incremental cost per responder] with apremilast vs. methotrexate is high. … These results could provide clinically and economically relevant implications for health care decision makers.”
http://www.cellceutix.com/new-blog/2016/10/5/otezla-fails-to-outperform-methotextrate-according-to-a-recent-study-1
Todays blog post isn't the best utilization for a blog imo. Leave that kind of stuff for the SA writers.
Todays post...
"Perfection is not attainable, but if we chase perfection we can catch
excellence." Vince Lombardi
Do your research! Play the TA. All posts are my opinion.
Recent IPIX News
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
